Dyne Announces Positive Results from DELIVER Trial for DMD at MDA Conference
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy DYN?
Source: Newsfilter
- DELIVER Trial Results: Dyne showcased positive outcomes from the DELIVER trial at the 2026 MDA Conference, demonstrating that z-rostudirsen significantly improved muscle function in DMD patients, particularly in long-term cardiopulmonary function, further validating the efficacy of its FORCE™ platform.
- Clinical Trial Design: The company will present the Phase 3 trial design for z-basivarsen in DM1, which is expected to set a new standard in the field, highlighting Dyne's forward-thinking and innovative approach to treating neuromuscular diseases.
- Multiple Presentations: Dyne will conduct five presentations, including three oral reports covering DMD, DM1, and Pompe disease, showcasing its robust pipeline in neuromuscular disorders and enhancing investor confidence.
- Cutting-Edge Data Release: The company will also release new preclinical data for DYNE-401 in Pompe disease, indicating potential functional improvements with infrequent dosing, further solidifying Dyne's leadership position in neuromuscular disease therapies.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy DYN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on DYN
Wall Street analysts forecast DYN stock price to rise
9 Analyst Rating
7 Buy
2 Hold
0 Sell
Strong Buy
Current: 15.250
Low
17.00
Averages
39.33
High
60.00
Current: 15.250
Low
17.00
Averages
39.33
High
60.00
About DYN
Dyne Therapeutics, Inc. is a clinical-stage neuromuscular disease company. It is discovering and advancing therapeutics for people living with genetically driven neuromuscular diseases. Leveraging the modularity of its FORCE platform, it is developing targeted therapeutics that deliver to muscle and the central nervous system (CNS). It has a broad pipeline for neuromuscular diseases, including clinical programs for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD) and preclinical programs for facioscapulohumeral muscular dystrophy (FSHD) and Pompe disease. Its product candidate, DYNE-101, is being evaluated in ACHIEVE, an ongoing Phase I/II global clinical trial in patients with DM1. Its product candidate, DYNE-251, is being evaluated in DELIVER, an ongoing Phase I/II global clinical trial in patients with DMD who have mutations amenable to exon 51 skipping. Its other product candidates are DYNE-302 and DYNE-401. DYNE-302 addresses the genetic basis of FSHD.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Dyne Announces Positive Results from DELIVER Trial for DMD at MDA Conference
- DELIVER Trial Results: Dyne showcased positive outcomes from the DELIVER trial at the 2026 MDA Conference, demonstrating that z-rostudirsen significantly improved muscle function in DMD patients, particularly in long-term cardiopulmonary function, further validating the efficacy of its FORCE™ platform.
- Clinical Trial Design: The company will present the Phase 3 trial design for z-basivarsen in DM1, which is expected to set a new standard in the field, highlighting Dyne's forward-thinking and innovative approach to treating neuromuscular diseases.
- Multiple Presentations: Dyne will conduct five presentations, including three oral reports covering DMD, DM1, and Pompe disease, showcasing its robust pipeline in neuromuscular disorders and enhancing investor confidence.
- Cutting-Edge Data Release: The company will also release new preclinical data for DYNE-401 in Pompe disease, indicating potential functional improvements with infrequent dosing, further solidifying Dyne's leadership position in neuromuscular disease therapies.
See More
Dyne Therapeutics Receives Orphan Drug Designation for z-basivarsen, ACHIEVE Trial Shows Sustained Improvement
- Clinical Trial Progress: Z-basivarsen demonstrates sustained functional improvement in the ACHIEVE trial, particularly in muscle strength and function, with enrollment for the registrational expansion cohort expected to complete in early Q2 2026, further advancing treatment options.
- Orphan Drug Designation: The MHLW in Japan has granted z-basivarsen orphan drug status for myotonic dystrophy type 1 (DM1), highlighting the urgent need for new therapies and potentially providing up to 10 years of market exclusivity if approved.
- Multiple Designations: Z-basivarsen has received Breakthrough Therapy, Fast Track, and Orphan Drug designations from the FDA, along with Orphan Drug designation from the EMA, indicating its development potential and market recognition on a global scale.
- Treatment Need: DM1 affects approximately 40,000 people in the U.S. and 55,000 in the EU, and the development of z-basivarsen aims to address the significant unmet medical need, carrying important social and economic implications.
See More
Stocks to Consider Buying in 2026: Insights from Our Roundtable Experts, Including DoorDash and LVMH
Stock Picks Overview: The second installment of the 2026 Barron’s Roundtable features 30 stock picks from five investment experts, highlighting both well-known companies and lesser-known options.
Familiar Names Included: Among the stock picks are recognizable brands such as Home Depot, Starbucks, and Nike, indicating a mix of established and emerging investment opportunities.
Biodegradable Innovation: The article hints at a British company that has recently acquired a manufacturer of biodegradable sneaker midsoles, showcasing a trend towards sustainable products in the footwear industry.
Investment Insights: The Roundtable serves as a platform for sharing diverse investment strategies and insights, appealing to both seasoned investors and those looking to explore new market trends.
See More
Dyne Therapeutics Closes $402.5 Million Upsized Public Offering
- Upsized Offering: Dyne Therapeutics successfully closed an upsized public offering of 21,827,549 shares at $18.44 each, reflecting strong market demand for its therapeutic solutions and expected to provide substantial funding for future R&D initiatives.
- Significant Proceeds: The offering generated approximately $402.5 million in gross proceeds, which will be allocated to advancing clinical programs targeting muscle and central nervous system disorders, particularly myotonic dystrophy and Duchenne muscular dystrophy.
- Strong Underwriter Lineup: Morgan Stanley, Jefferies, Stifel, and Guggenheim Securities acted as joint book-running managers, enhancing investor confidence in the offering due to their market influence and expertise.
- Effective Registration Statement: The offering was conducted under a shelf registration statement on Form S-3 filed on March 5, 2024, ensuring compliance and transparency, which is likely to bolster investor trust in the company's future growth prospects.
See More
Dyne Therapeutics Closes $402.5 Million Upsized Public Offering
- Upsized Offering: Dyne Therapeutics successfully completed an upsized public offering of 21,827,549 shares at $18.44 per share, reflecting strong market confidence in its treatments for genetically driven neuromuscular diseases.
- Significant Proceeds: The offering generated approximately $402.5 million in gross proceeds, which will be allocated to advancing clinical programs, particularly for myotonic dystrophy and Duchenne muscular dystrophy, enhancing the company's therapeutic pipeline.
- Strong Underwriter Lineup: The involvement of Morgan Stanley, Jefferies, Stifel, and Guggenheim Securities as joint book-running managers bolsters market trust and enhances Dyne's brand reputation in the biotech sector.
- Effective Registration Statement: The offering was conducted under an S-3 registration statement filed on March 5, 2024, ensuring compliance and streamlining the financing process, thereby increasing the company's flexibility in capital markets.
See More
Oppenheimer Upgrades Dyne Ahead of Avidity's Upcoming Trial Results
Analyst Upgrade: Oppenheimer upgraded Dyne Therapeutics (DYN) to Outperform from Perform, raising the price target from $11 to $40 per share, citing positive data expectations from Avidity Biosciences' late-stage trial.
Market Reaction: Following Novartis' $12 billion acquisition of Avidity, Dyne's shares surged over 40%, indicating strong market confidence in Dyne's potential upside.
Future Expectations: Analyst Kostas Biliouris anticipates nearly 50% upside for DYN, driven by the expected Phase 3 readout in H2 2026 for Avidity's RNA therapy targeting myotonic dystrophy type 1.
Upcoming Catalysts: Biliouris expects Dyne's DM1 program for z-basivarsen to succeed, with potential catalysts including an FDA review of the company's Duchenne muscular dystrophy candidate.
See More
Dyne Announces Positive Results from DELIVER Trial for DMD at MDA Conference
- DELIVER Trial Results: Dyne showcased positive outcomes from the DELIVER trial at the 2026 MDA Conference, demonstrating that z-rostudirsen significantly improved muscle function in DMD patients, particularly in long-term cardiopulmonary function, further validating the efficacy of its FORCE™ platform.
- Clinical Trial Design: The company will present the Phase 3 trial design for z-basivarsen in DM1, which is expected to set a new standard in the field, highlighting Dyne's forward-thinking and innovative approach to treating neuromuscular diseases.
- Multiple Presentations: Dyne will conduct five presentations, including three oral reports covering DMD, DM1, and Pompe disease, showcasing its robust pipeline in neuromuscular disorders and enhancing investor confidence.
- Cutting-Edge Data Release: The company will also release new preclinical data for DYNE-401 in Pompe disease, indicating potential functional improvements with infrequent dosing, further solidifying Dyne's leadership position in neuromuscular disease therapies.
See More
Dyne Therapeutics Receives Orphan Drug Designation for z-basivarsen, ACHIEVE Trial Shows Sustained Improvement
- Clinical Trial Progress: Z-basivarsen demonstrates sustained functional improvement in the ACHIEVE trial, particularly in muscle strength and function, with enrollment for the registrational expansion cohort expected to complete in early Q2 2026, further advancing treatment options.
- Orphan Drug Designation: The MHLW in Japan has granted z-basivarsen orphan drug status for myotonic dystrophy type 1 (DM1), highlighting the urgent need for new therapies and potentially providing up to 10 years of market exclusivity if approved.
- Multiple Designations: Z-basivarsen has received Breakthrough Therapy, Fast Track, and Orphan Drug designations from the FDA, along with Orphan Drug designation from the EMA, indicating its development potential and market recognition on a global scale.
- Treatment Need: DM1 affects approximately 40,000 people in the U.S. and 55,000 in the EU, and the development of z-basivarsen aims to address the significant unmet medical need, carrying important social and economic implications.
See More
Stocks to Consider Buying in 2026: Insights from Our Roundtable Experts, Including DoorDash and LVMH
Stock Picks Overview: The second installment of the 2026 Barron’s Roundtable features 30 stock picks from five investment experts, highlighting both well-known companies and lesser-known options.
Familiar Names Included: Among the stock picks are recognizable brands such as Home Depot, Starbucks, and Nike, indicating a mix of established and emerging investment opportunities.
Biodegradable Innovation: The article hints at a British company that has recently acquired a manufacturer of biodegradable sneaker midsoles, showcasing a trend towards sustainable products in the footwear industry.
Investment Insights: The Roundtable serves as a platform for sharing diverse investment strategies and insights, appealing to both seasoned investors and those looking to explore new market trends.
See More
Dyne Therapeutics Closes $402.5 Million Upsized Public Offering
- Upsized Offering: Dyne Therapeutics successfully closed an upsized public offering of 21,827,549 shares at $18.44 each, reflecting strong market demand for its therapeutic solutions and expected to provide substantial funding for future R&D initiatives.
- Significant Proceeds: The offering generated approximately $402.5 million in gross proceeds, which will be allocated to advancing clinical programs targeting muscle and central nervous system disorders, particularly myotonic dystrophy and Duchenne muscular dystrophy.
- Strong Underwriter Lineup: Morgan Stanley, Jefferies, Stifel, and Guggenheim Securities acted as joint book-running managers, enhancing investor confidence in the offering due to their market influence and expertise.
- Effective Registration Statement: The offering was conducted under a shelf registration statement on Form S-3 filed on March 5, 2024, ensuring compliance and transparency, which is likely to bolster investor trust in the company's future growth prospects.
See More
Dyne Therapeutics Closes $402.5 Million Upsized Public Offering
- Upsized Offering: Dyne Therapeutics successfully completed an upsized public offering of 21,827,549 shares at $18.44 per share, reflecting strong market confidence in its treatments for genetically driven neuromuscular diseases.
- Significant Proceeds: The offering generated approximately $402.5 million in gross proceeds, which will be allocated to advancing clinical programs, particularly for myotonic dystrophy and Duchenne muscular dystrophy, enhancing the company's therapeutic pipeline.
- Strong Underwriter Lineup: The involvement of Morgan Stanley, Jefferies, Stifel, and Guggenheim Securities as joint book-running managers bolsters market trust and enhances Dyne's brand reputation in the biotech sector.
- Effective Registration Statement: The offering was conducted under an S-3 registration statement filed on March 5, 2024, ensuring compliance and streamlining the financing process, thereby increasing the company's flexibility in capital markets.
See More
Oppenheimer Upgrades Dyne Ahead of Avidity's Upcoming Trial Results
Analyst Upgrade: Oppenheimer upgraded Dyne Therapeutics (DYN) to Outperform from Perform, raising the price target from $11 to $40 per share, citing positive data expectations from Avidity Biosciences' late-stage trial.
Market Reaction: Following Novartis' $12 billion acquisition of Avidity, Dyne's shares surged over 40%, indicating strong market confidence in Dyne's potential upside.
Future Expectations: Analyst Kostas Biliouris anticipates nearly 50% upside for DYN, driven by the expected Phase 3 readout in H2 2026 for Avidity's RNA therapy targeting myotonic dystrophy type 1.
Upcoming Catalysts: Biliouris expects Dyne's DM1 program for z-basivarsen to succeed, with potential catalysts including an FDA review of the company's Duchenne muscular dystrophy candidate.
See More
